Bortezomib in Combination With CC-5013 in Patients With Relapsed/Refractory Multiple Myeloma
Status:
Completed
Trial end date:
2014-07-01
Target enrollment:
Participant gender:
Summary
The purpose if this study is to evaluate the side effects of the combination of bortezomib
and Revlimid (CC-5013) in patients with relapsed and relapsed/refractory multiple myeloma.
Phase:
Phase 1
Details
Lead Sponsor:
Dana-Farber Cancer Institute
Collaborators:
Beth Israel Deaconess Medical Center Brigham and Women's Hospital H. Lee Moffitt Cancer Center and Research Institute